SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-17-002787
Filing Date
2017-04-21
Accepted
2017-04-21 16:10:20
Documents
4
Period of Report
2017-06-15
Effectiveness Date
2017-04-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A acrs-20170615xdef14a.htm DEF 14A 692252
2 GRAPHIC acrs20170615xdef14a001.jpg GRAPHIC 4750
3 GRAPHIC acrs20170615xdef14a002.gif GRAPHIC 62245
4 GRAPHIC acrs20170615xdef14a003.gif GRAPHIC 41141
  Complete submission text file 0001558370-17-002787.txt   842667
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37581 | Film No.: 17776014
SIC: 2834 Pharmaceutical Preparations